A detailed history of Prudential Financial Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Prudential Financial Inc holds 60,798 shares of PTGX stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,798
Holding current value
$2.39 Million
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $2.05 Million - $2.88 Million
60,798 New
60,798 $2.73 Million
Q1 2023

May 12, 2023

BUY
$10.78 - $25.38 $725,418 - $1.71 Million
67,293 New
67,293 $1.55 Million
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $162,330 - $586,781
-22,993 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$23.34 - $36.08 $165,994 - $256,600
-7,112 Reduced 23.62%
22,993 $544,000
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $3,349 - $7,049
-190 Reduced 0.63%
30,105 $1.03 Million
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $5,827 - $22,360
450 Added 1.51%
30,295 $537,000
Q2 2021

Aug 16, 2021

SELL
$25.57 - $44.88 $96,398 - $169,197
-3,770 Reduced 11.22%
29,845 $1.34 Million
Q1 2021

May 12, 2021

SELL
$19.02 - $31.15 $194,194 - $318,041
-10,210 Reduced 23.3%
33,615 $871,000
Q4 2020

Feb 16, 2021

SELL
$18.49 - $25.13 $206,903 - $281,204
-11,190 Reduced 20.34%
43,825 $884,000
Q3 2020

Nov 16, 2020

SELL
$15.19 - $22.4 $186,685 - $275,296
-12,290 Reduced 18.26%
55,015 $1.08 Million
Q2 2020

Aug 12, 2020

SELL
$6.19 - $18.84 $31,166 - $94,859
-5,035 Reduced 6.96%
67,305 $1.19 Million
Q1 2020

May 12, 2020

BUY
$5.4 - $9.22 $111,510 - $190,393
20,650 Added 39.95%
72,340 $510,000
Q4 2019

Feb 11, 2020

BUY
$4.69 - $13.45 $185,677 - $532,485
39,590 Added 327.19%
51,690 $364,000
Q2 2018

Aug 13, 2018

SELL
$5.99 - $9.1 $8,805 - $13,377
-1,470 Reduced 10.83%
12,100 $0
Q1 2018

May 04, 2018

BUY
$8.46 - $23.08 $114,802 - $313,195
13,570 New
13,570 $0

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.